SCHEMBL1890213

SCHEMBL1890213

CCc1nnc(NC(=O)c2c(O)cc(C)n(C)c2=O)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 3/20 0.50
LMNA P02545 2/20 0.50
HTT P42858 2/20 0.50
HSD17B10 Q99714 1/20 0.50
SMN1; SMN2 Q16637 5/20 0.49
MAPT P10636 1/20 0.49
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
NPSR1 Q6W5P4 3/20 0.48
POLB P06746 2/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
OPRK1 P41145 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1893161 0.85 RAB9A (0.52) ALDH1A1LMNASMN1; SMN2MAPTNPC1
SCHEMBL1886903 0.79 RAB9A (0.48) ALDH1A1KDM4EHTTHSD17B10SMN1; SMN2
SCHEMBL1891491 0.78 SMN1; SMN2 (0.51) ALDH1A1KDM4ELMNAHTTSMN1; SMN2
SCHEMBL1891165 0.77 RAB9A (0.51) ALDH1A1KDM4ELMNAHSD17B10SMN1; SMN2
SCHEMBL1893447 0.77 AHR (0.51) ALDH1A1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL12508094 0.75 RAB9A (0.55) SMN1; SMN2NPC1RAB9APOLBALOX15
SCHEMBL1889947 0.75 RAB9A (0.51) ALDH1A1KDM4ELMNAHTTSMN1; SMN2
SCHEMBL1888774 0.75 RAB9A (0.51) ALDH1A1KDM4EHTTSMN1; SMN2MAPT
SCHEMBL12417679 0.75 MAPT (0.51) ALDH1A1KDM4ELMNAHTTHSD17B10
SCHEMBL12417686 0.72 RAB9A (0.53) ALDH1A1KDM4ELMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1887002-B1 CARBOXAMIDE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2015-08-26 EP disclosed
US-8304437-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-06 US disclosed
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME ARIMORI SADAYUKI 2011-07-14 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
EP-1887002-A1 CARBOXAMIDE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076063-A1 Carboxamide compound and use of the same CBR3, SIRT2, SIRT1 ALDH1A1 3016/4885KDM4E 988/4885LMNA 1426/4885
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME CBR3, SIRT2, SIRT1 ALDH1A1 3016/4885KDM4E 988/4885LMNA 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.